Found 95 matching trials
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) PHASE3 The primary objective of the study is to compare sacituzumab tirumotecan co...
Show More Location
Mayo Clinic in Arizona - Phoenix ( Site 0147)
Learn More & Join Trial
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) PHASE3 The purpose of this study is to evaluate sacituzumab tirumotecan versus pem...
Show More Status
Active Not Recruiting
Location
Kaiser Permanente - Oakland ( Site 0054)
Learn More & Join Trial
ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma PHASE2 This is a single-arm, single-center, exploratory clinical study. The study ...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) PHASE3 This study will compare how safe and effective sacituzumab tirumotecan is v...
Show More Status
Active Not Recruiting
Location
Banner MD Anderson Cancer Center ( Site 0119)
Learn More & Join Trial
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) PHASE3 Researchers are looking for new ways to treat people with endometrial cance...
Show More Status
Active Not Recruiting
Location
USA Mitchell Cancer Institute ( Site 4142)
Learn More & Join Trial
Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations PHASE3 The goal of this clinical trial is to evaluate the efficacy and safety of s...
Show More Location
Fudan University Shanghai Cancer Center, Shanghai, Shanghai 200032
Learn More & Join Trial
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) PHASE1 Researchers are looking for new ways to treat esophageal squamous cell carc...
Show More Location
UPMC Hillman Cancer Center ( Site 1904)
Learn More & Join Trial
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases PHASE2 This is a prospective, open-label, multi-center, single-arm clinical trial...
Location
Zhejiang Cancer Hospital
Learn More & Join Trial
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) PHASE2 This is an single-arm, multicenter phase II study to evaluate the safety an...
Show More Location
West China Hospital of Sichuan University
Learn More & Join Trial
Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma PHASE2 This is a single-center, open-label phase 2 study evaluating sacituzumab ti...
Show More Location
Multiple Locations
Learn More & Join Trial